Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Labcorp Holdings ( (LH) ).
On August 27, 2025, Labcorp Holdings announced that its executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The event will be available via a live audio webcast on the company’s Investor Relations website, potentially enhancing Labcorp’s visibility and engagement with stakeholders in the healthcare industry.
The most recent analyst rating on (LH) stock is a Buy with a $311.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
Labcorp Holdings demonstrates strong financial management and positive technical indicators, contributing to a favorable outlook. The company’s robust earnings call and strategic initiatives further enhance its position. However, high valuation metrics and potential regulatory risks temper the overall score.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
Labcorp Holdings Inc. is a global leader in innovative and comprehensive laboratory services, providing diagnostics and drug development capabilities. The company supports doctors, hospitals, pharmaceutical companies, researchers, and patients, serving clients in approximately 100 countries. Labcorp’s nearly 70,000 employees perform over 700 million tests annually and supported more than 75% of the new drugs and therapeutic products approved by the FDA in 2024.
Average Trading Volume: 695,350
Technical Sentiment Signal: Buy
Current Market Cap: $23.14B
Find detailed analytics on LH stock on TipRanks’ Stock Analysis page.